BioVie says Phase 2 SUNRISE-PD trial shows bezisterim improves motor and non-motor symptoms in early Parkinson’s disease
BIVI•Biomarker and safety findings
Biomarker readouts pointed to reduced inflammation with signals consistent with potential neuroprotective effects.
The safety profile was comparable to placebo, supporting plans to use the data to shape a potential Phase 3 study.
Phase 2 SUNRISE-PD topline results
BioVie reported topline Phase 2 SUNRISE-PD results for bezisterim in early Parkinson’s disease.
Results have been announced now; a detailed review is scheduled for an Aug. 12, 2026 conference call.
Patients on bezisterim showed broader clinical improvement versus placebo across motor function, daily activities, and non-motor symptoms.
